2. Search Result
Search Result
Results for "

ChoK

" in MedChemExpress (MCE) Product Catalog:

40

Inhibitors & Agonists

6

Peptides

5

Inhibitory Antibodies

1

Natural
Products

2

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-122675
    ACG416B

    		Choline Kinase Cancer
    ACG416B (compound 18) is a potent inhibitor of ChoK (choline kinase) with an IC50 of 0.4 μM. ACG416B renders higher ChoK inhibitory and antiproliferative activities against the HT-29 human colon cancer cell .
    ACG416B
  • HY-122140
    ACG548B

    		Cholinesterase (ChE) Neurological Disease
    ACG548B (compound 24) is a potent inhibitor of acetyl- and butyrylcholinesterase (AChE and BChE) with IC50s of 1.78 and 0.496 μM, respectively. ACG548B has higher AChE affinity and selectivity over BChE and ChoK (choline kinase). ACG548B can be uesd for the study of myasthenia gravis and neuromuscular blockade .
    ACG548B
  • HY-101144
    RSM-932A

    TCD-717

    		 Others Cancer
    RSM-932A (TCD-717) is a specific ChoKα inhibitor with IC50s of 1 and 33 μM for human recombinant ChoKα and ChoKβ enzymes, respectively. RSM-932A acts as the “first in humans” compound targeting ChoKα. RSM-932A is potent in vitro anti-proliferative and in vivo anti-tumoral activity against human xenografts in mice, showing high efficacy with low toxicity profiles .
    RSM-932A
  • HY-115463
    EB-3D
    2 Publications Verification

    		 AMPK Apoptosis Cancer
    EB-3D is a potent and selective choline kinase α (ChoKα) inhibitor, with an IC50 of 1 μM for ChoKα1. EB-3D exerts effects on ChoKα expression, AMPK activation, apoptosis, endoplasmic reticulum stress and lipid metabolism. EB-3D exhibits a potent antiproliferative activity in a panel of T-leukemia cell lines. Anti-cancer activity .
    EB-3D
  • HY-108003
    MM 07

    		Apelin Receptor (APJ) Cardiovascular Disease
    MM 07 is a biased apelin receptor agonist, with a KD of 300 nM in CHO-K1 cells and a KD of 172 nM in human heart.
    MM 07
  • HY-152195
    ChoKα inhibitor-5

    		Apoptosis Cancer
    ChoKα inhibitor-5 is a sulphur-containing choline kinase inhibitor. ChoKα inhibitor-5 can inhibit HChoK α1 with an IC50 value of 0.64 μM. ChoKα inhibitor-5 also can induce apoptosis. ChoKα inhibitor-5 can be used for the research of cancer .
    ChoKα inhibitor-5
  • HY-152191
    ChoKα inhibitor-3

    		Apoptosis Cancer
    ChoKα inhibitor-3 is a sulphur-containing choline kinase inhibitor. ChoKα inhibitor-3 can inhibit HChoK α1 with an IC50 value of 0.66 μM. ChoKα inhibitor-3 also can induce apoptosis. ChoKα inhibitor-3 can be used for the research of cancer .
    ChoKα inhibitor-3
  • HY-162799
    ChoKα inhibitor-6

    		Choline Kinase Cancer
    ChoKα inhibitor-6 (compound Fa22) is a less specific ChoKα1 inhibitor with antitumor activity .
    ChoKα inhibitor-6
  • HY-152193
    ChoKα inhibitor-4

    		Apoptosis Cancer
    ChoKα inhibitor-4 is a bioisosteric inhibitor of HChoK α1 (IC50=0.66 μM), with inhibitory and antiproliferative effect on cancer cells. ChoKα inhibitor-4 induces apoptosis via mitochondrial pathway, and reduces anti-apoptotic proteins expression .
    ChoKα inhibitor-4
  • HY-114081A
    Hemicholinium chloride

    HC-3 chloride

    		 Choline Kinase Neurological Disease
    Hemicholinium chloride (HC-3) is a choline kinase (ChoK) inhibitor. Hemicholinium chloride Hemicholinium chloride induces ataxia and muscular weakness .
    Hemicholinium chloride
  • HY-P99888
    Pimurutamab

    		EGFR Others
    Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells .
    Pimurutamab
  • HY-P99870
    Eblasakimab

    ASLAN004; CSL-334; MK-6105

    		 Interleukin Related Others
    Eblasakimab (ASLAN004; CSL-334) is a human IgG4 antibody that specifically targets IL13RA1 and is primarily expressed by CHO-K1 cells .
    Eblasakimab
  • HY-I0383
    Canagliflozin hemihydrate
    Maximum Cited Publications
    41 Publications Verification

    JNJ 28431754 hemihydrate

    		 SGLT Metabolic Disease Cancer
    Canagliflozin hemihydrate (JNJ28431754 hemihydrate) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .
    Canagliflozin hemihydrate
  • HY-120337
    V-11-0711

    		Choline Kinase Cancer
    V-11-0711 is a potent and selective choline kinase alpha (ChoKα) inhibitor with an IC50 of 20 nM. V-11-0711 causes a reversible growth arrest in HeLa cells .
    V-11-0711
  • HY-10451
    Canagliflozin
    Maximum Cited Publications
    41 Publications Verification

    JNJ 28431754

    		 SGLT Metabolic Disease Cancer
    Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .
    Canagliflozin
  • HY-P990009
    Nisevokitug

    NIS-793

    		 TGF-beta/Smad Cancer
    Nisevokitug (NIS-793) is a human, IgG2λ antibody targeting TGF-β (TGFB1/TGFB2). Nisevokitug is expressed by CHO-K1 cells .
    Nisevokitug
  • HY-124104
    Aldicarb sulfoxide

    		Drug Metabolite Cardiovascular Disease Metabolic Disease
    Aldicarb sulfoxide is a metabolite of Aldicarb. Aldicarb sulfoxide affects the glutathione-linked enzymes in CHO-K1 cells. Aldicarb sulfoxide inhibits cholinesterase (ChE) and carboxylesterase (CaE) with IC50 of 10 μM for both in zebrafish .
    Aldicarb sulfoxide
  • HY-100962A
    AG 99

    Tyrphostin 46; Tyrphostin AG 99

    		 Tyrosinase Cancer
    AG 99 (Tyrphostin 46), a tyrphostin derivative, is a tyrosine kinase inhibitor that increases sister chromatid exchange frequency in transformed CHO-K1 and primary CHE cells. AG 99 is promising for research of proliferative diseases .
    AG 99
  • HY-10451S2
    Canagliflozin-d6

    JNJ 28431754-d6

    		 SGLT Metabolic Disease
    Canagliflozin-d6 is the deuterium labeled Canagliflozin . Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .
    Canagliflozin-d6
  • HY-123335
    L-796778

    		Somatostatin Receptor Others
    L-796778 is an agonist of the hsst3 receptor. In CHO-K1 cells expressing the hsst3 receptor, L-796778 is a partial agonist that inhibits forskolin (HY-15371)-stimulated cAMP production with an IC50 value of 18 nM .
    L-796778
  • HY-10451R
    Canagliflozin (Standard)

    JNJ 28431754 (Standard)

    		 Reference Standards SGLT Metabolic Disease Cancer
    Canagliflozin (Standard) is the analytical standard of Canagliflozin. This product is intended for research and analytical applications. Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .
    Canagliflozin (Standard)
  • HY-P5872
    Jingzhaotoxin XI

    JZTX-XI

    		 Sodium Channel Neurological Disease
    Jingzhaotoxin XI (JZTX-XI) is a sodium conductance inhibitor with an IC50 of 124 nM. Jingzhaotoxin XI slows the fast inactivation (EC50=1.18±0.2 μM) of Nav1.5 expressed in Chinese hamster ovary (CHO-K1) cells .
    Jingzhaotoxin XI
  • HY-P3789
    Prolactin-Releasing Peptide (12-31), rat

    		Orphan Receptor Metabolic Disease
    Prolactin-Releasing Peptide (12-31), rat is a fragment of the prolactin releasing peptide (PrRP). Prolactin-Releasing Peptide (12-31), rat shows high affinity for GPR10 receptors. Prolactin-Releasing Peptide (12-31), stimulates calcium mobilization in CHOK1 cells transfected with the PrRP receptor .
    Prolactin-Releasing Peptide (12-31), rat
  • HY-123335A
    L-796778 acetate

    		Somatostatin Receptor Neurological Disease
    L-796778 acetate is a selective agonist of the sst3 receptor. In CHO-K1 cells expressing the hsst3 receptor, L-796778 acetate is a partial agonist that inhibits Forskolin (HY-15371)-stimulated cAMP production with an IC50 value of 18 nM. L-796778 acetate has anticonvulsant effect .
    L-796778 acetate
  • HY-124104S
    Aldicarb sulfoxide-d3

    		Isotope-Labeled Compounds Metabolic Disease
    Aldicarb sulfoxide-d3 is the deuterium labled Aldicarb sulfoxide (HY-124104). Aldicarb sulfoxide is a metabolite of Aldicarb. Aldicarb sulfoxide affects the glutathione-linked enzymes in CHO-K1 cells. Aldicarb sulfoxide inhibits cholinesterase (ChE) and carboxylesterase (CaE) with IC50 of 10 μM for both in zebrafish .
    Aldicarb sulfoxide-d3
  • HY-117617
    CAY10669

    		Histone Acetyltransferase Cancer
    CAY10669 (compound 6d) is an anacardic acid (HY-N2020) derivative that inhibits histone acetyltransferase PCAF with an IC50 of 662 μM . CAY10669 enhances the SAHA-induced acetylation in HEPG2 cells, exhibits cytotoxicity in zebrafish embryo, promotes transgene expression in CHO-K1 cells .
    CAY10669
  • HY-136895
    AZ12672857

    		Prostaglandin Receptor Cancer
    AZ12672857 is an orally active inhibitor of EphB4 (IC50=1.3 nM) and Src kinases. AZ12672857 shows good inhibition of proliferation of c-Src transfected 3T3 cells (IC50=2 nM) as well as autophosphorylation of EphB4 in transfected CHO-K1 cells (IC50=9 nM) .
    AZ12672857
  • HY-P990006
    Duvakitug

    TEV-48574

    		 TNF Receptor Inflammation/Immunology
    Duvakitug (TEV-48574) is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) .
    Duvakitug
  • HY-RS21311
    Chka Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Chka Mouse Pre-designed siRNA Set A contains three designed siRNAs for Chka gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Chka Mouse Pre-designed siRNA Set A
    Chka Mouse Pre-designed siRNA Set A
  • HY-161247
    5-HT2A antagonist 2

    		5-HT Receptor Metabolic Disease
    5HT2A antagonist 2 is an orally active, selective antagonist for 5HT2A with IC50 of 14 nM. 5-HT2A antagonist 2 exhibits good chemical, hepatocyte, and plasma stability, without significant cytotoxicity in cell lines VERO, HFL-1, L929, NIH3T3, CHO-K1 .
    5-HT2A antagonist 2
  • HY-P991114
    Adezkibart

    		FLT3 Inflammation/Immunology
    Adezkibart is a human monoclonal antibody immunosuppressant targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Adezkibart is found in the Chinese hamster ovary cell line CHO-K1, which binds to FLT3LG to block the relevant signaling pathway, inhibits the immune response, and exerts immunosuppressive activity. Adezkibart is promising for research of immune-related diseases .
    Adezkibart
  • HY-174259
    Muscarinic M4 modulator-1

    		mAChR Neurological Disease
    Muscarinic M4 modulator-1 is a Muscarinic M4 receptor positive allosteric modulator. Muscarinic M4 modulator-1 activates the muscarinic M4 receptor with allosteric potency EC50 s of 14 and 3 Nm in CHO-K1 cells and HEK293 cells. Muscarinic M4 modulator-1 has an antipsychotic-like activity, promising for psychiatric and/or neurological disorders research .
    Muscarinic M4 modulator-1
  • HY-137749A
    MANT-dADP trisodium

    2'-Deoxy-3'-MANT-ADP trisodium

    		 Biochemical Assay Reagents Others
    MANT-dADP (trisodium) (2'-Deoxy-3'-MANT-ADP (trisodium)) is a fluorescent nucleotide derivative, with an emission maximum of 453 nm upon excitation at 350 nm. MANT-dADP (trisodium) can decrease inositol phoshate formation in CHO-K1 cells that express human purinergic P2Y12 receptor. MANT-dADP (trisodium) can be studied in research on the interaction between cardiac troponin I and myofibrils .
    MANT-dADP trisodium
  • HY-P4146
    Survodutide

    BI 456906

    		 GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide
  • HY-P4146A
    Survodutide TFA

    BI 456906 TFA

    		 GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide TFA
  • HY-171854
    SB-583355

    		G2A (GPR132) Neurological Disease Inflammation/Immunology
    SB-583355 (Compound 56) is a potent G2A antagonist. SB-583355 can be prepared by a Suzuki reaction between 4-methoxyphenyl boronic acid and 3-bromo-4-hydroxybenzoic acid following the conditions followed by an amide coupling reaction. SB-583355 blocks the activation of G2A mediated either by 9-HOPE or T-10148 in human G2A expressing CHO-K1 cells. SB-583355 can be studied in research for inflammation, myeloid leukemia, and neuropathic pain .
    SB-583355
  • HY-P0165B
    Taspoglutide acetate

    ITM077 acetate; R1583 acetate; BIM51077 acetate

    		 GLP Receptor Metabolic Disease
    Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an Ki value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC50 = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .
    Taspoglutide acetate
  • HY-176546
    NK3R-IN-2

    		Neurokinin Receptor Endocrinology
    NK3R-IN-2 is an orally active NK3R inhibitor with an IC50 of 330.50 nM for human NK3R. NK3R-IN-2 can pass through the blood-brain barrier. NK3R-IN-2 has excellent NK3R binding affinity (IC50 = 87.31 nM) in CHO-K1 cells. NK3R-IN-2 effectively inhibits the level of luteinizing hormone (LH). NK3R-IN-2 can be used for research on hormone related conditions .
    NK3R-IN-2
  • HY-132225
    SB 206553

    		5-HT Receptor Inflammation/Immunology
    SB 206553 is a 5-HT2C inverse agonist. SB 206553 can attenuate methamphetamine-seeking in rats. SB 206553 has activity for 5-HT2 receptor ligands in HEK-293 or CHO-K1 cells expressing human recombinant 5-HT2 receptors with pKi values of 5.6 nM (5-HT2A), 7.7 nM (5-HT2B) and 7.8 nM (5-HT2C), respectively. SB 206553 can be used for the research of psychostimulant abuse disorders .
    SB 206553
  • HY-113513
    5-HEPE

    		Others Cancer
    5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.
    5-HEPE

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: